Our Law Firm has advised the Kvarko fund on its investment in Biovetika sp. z o.o., which carries out the project entitled “Innovative technology in the production of LPS vaccines against Gram-negative bacteria”. Total funds acquired by Biovetika sp. z o.o. amounted to PLN 1 million.
The fund was represented by Jarosław Rudy, Partner and Advisor at our Law Firm.
The purpose of the “Innovative technology in the production of LPS vaccines against Gram-negative bacteria” project carried out by Biovetika sp. z o.o. was to develop a method of production of veterinary vaccines against bacteria whose cell membrane contains bacterial lipopolysaccharide (LPS), called endotoxin. The vaccines, which are to be used for breeding animals (poultry, pigs), will compete with whole cell anti-microbial vaccines that are already available in the market and are considered by veterinary surgeons as ineffective or poorly effective. The application of the new vaccines could reduce the rate of infection of poultry and pigs with Gram-negative bacteria.
The project is carried out on the basis of the experience and achievements of scientific staff of the Institute of Immunology and Experimental Therapy of the Polish Academy of Science in Wrocław.